Trial · NCT04818671
Results by group33
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 33
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of AEs, SAEs and AESIs | Efgartigimod PH20 SC | Number of AEs | 3325 | events | |
| Number of AEs, SAEs and AESIs | Efgartigimod PH20 SC | Number of SAEs | 107 | events | |
| Number of AEs, SAEs and AESIs | Efgartigimod PH20 SC | Number of AESIs | 420 | events | |
| MG-ADL Total Score Changes From Baseline | Efgartigimod PH20 SC | Cycle 1, Week 1 | -2.2 | Standard Error 0.20 | score on a scale |
| MG-ADL Total Score Changes From Baseline | Efgartigimod PH20 SC | Cycle 1, Week 2 | -3.4 | Standard Error 0.21 | score on a scale |
| MG-ADL Total Score Changes From Baseline | Efgartigimod PH20 SC | Cycle 1, Week 3 | -3.9 | Standard Error 0.22 | score on a scale |
| MG-ADL Total Score Changes From Baseline | Efgartigimod PH20 SC | Cycle 1, Week 4 | -4.0 | Standard Error 0.23 | score on a scale |
| Percent Change in Total IgG Levels From Baseline | Efgartigimod PH20 SC | -62.6 | Standard Error 0.93 | Percent change | |
| Percent Change in AChR-Ab From Baseline in AChR-Ab Seropositive Participants | Efgartigimod PH20 SC | -57.6 | Standard Error 2.29 | Percent change | |
| Efgartigimod Serum Concentrations | Efgartigimod PH20 SC | 21693 | Standard Deviation 8242 | ng/mL | |
| Incidence of ADAs Against Efgartigimod Over Time | Efgartigimod PH20 SC | 35 | Participants | ||
| Incidence of NAbs Against Efgartigimod Over Time | Efgartigimod PH20 SC | 11 | Participants | ||
| Incidence of Antibodies Against rHuPH20 Over Time | Efgartigimod PH20 SC | 49 | Participants | ||
| Incidence of NAbs Against rHuPH20 Over Time | Efgartigimod PH20 SC | 1 | Participants | ||
| Changes in Total MG-QoL15r From Baseline | Efgartigimod PH20 SC | Cycle 1, Week 1 | -2.5 | Standard Error 0.29 | score on a scale |
| Changes in Total MG-QoL15r From Baseline | Efgartigimod PH20 SC | Cycle 1, Week 2 | -3.7 | Standard Error 0.34 | score on a scale |
| Changes in Total MG-QoL15r From Baseline | Efgartigimod PH20 SC | Cycle 1, Week 3 | -4.5 | Standard Error 0.38 | score on a scale |
| Changes in Total MG-QoL15r From Baseline | Efgartigimod PH20 SC | Cycle 1, Week 4 | -4.7 | Standard Error 0.39 | score on a scale |
| Changes in EQ-5D-5L VAS Score From Baseline | Efgartigimod PH20 SC | 13.9 | Standard Error 1.32 | score on a scale | |
| Percent of Participants or Caregivers by Number of Training Visits Needed to be Competent to Start Self- or Caregiver-Supported Administration | Efgartigimod PH20 SC | 0 visits | 4.8 | Percent of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04818671/results